Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: INCY EXEL ACAD RDUS ENTA CORT ANAB LGND AMLX PBYI

| Held by: IJR VTI VB IWM VBR AVUV VXF SPSM IJT IWN

Index	RUT	P/E	48.80	EPS (ttm)	0.45	Insider Own	3.09%	Shs Outstand	42.97M	Perf Week	3.67%
Market Cap	936.57M	Forward P/E	6.39	EPS next Y	3.41	Insider Trans	-4.45%	Shs Float	41.69M	Perf Month	-2.11%
Enterprise Value	1.12B	PEG	1.01	EPS next Q	0.90	Inst Own	114.73%	Short Float	18.90%	Perf Quarter	-8.76%
Income	21.44M	P/S	1.31	EPS this Y	-7.66%	Inst Trans	-8.93%	Short Ratio	9.19	Perf Half Y	-12.89%
Sales	716.79M	P/B	1.29	EPS next Y	15.32%	ROA	1.52%	Short Interest	7.88M	Perf YTD	-15.88%
Book/sh	16.93	P/C	3.80	EPS next 5Y	6.33%	ROE	2.90%	52W High	27.64 -21.24%	Perf Year	-17.94%
Cash/sh	5.73	P/FCF	7.54	EPS past 3/5Y	- -51.99%	ROIC	1.88%	52W Low	18.80 15.80%	Perf 3Y	-46.58%
Dividend Est.	-	EV/EBITDA	7.66	Sales past 3/5Y	8.98% 10.73%	Gross Margin	71.17%	Volatility	3.70% 4.71%	Perf 5Y	-71.69%
Dividend TTM	-	EV/Sales	1.56	EPS Y/Y TTM	123.74%	Oper. Margin	7.64%	ATR (14)	0.95	Perf 10Y	-61.83%
Dividend Ex-Date	-	Quick Ratio	3.78	Sales Y/Y TTM	3.14%	Profit Margin	2.99%	RSI (14)	50.84	Recom	2.14
Dividend Gr. 3/5Y	- -	Current Ratio	5.26	EPS Q/Q	103.93%	SMA20	5.41%	Beta	0.21	Target Price	29.71
Payout	-	Debt/Eq	0.58	Sales Q/Q	6.49%	SMA50	-6.44%	Rel Volume	0.89	Prev Close	21.45
Employees	790	LT Debt/Eq	0.57	Earnings	Feb 26 AMC	SMA200	-9.41%	Avg Volume	857.23K	Price	21.77
IPO	Feb 03, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.32% -0.88%	Trades		Volume	760,211	Change	1.49%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Equal Weight	$27
Nov-17-25	Initiated	H.C. Wainwright	Buy
Jul-25-25	Upgrade	Truist	Hold → Buy	$30
Jan-30-25	Upgrade	Truist	Sell → Hold	$8 → $25
Aug-13-24	Downgrade	Truist	Buy → Sell	$30 → $8
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$37 → $14
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $11
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight	$45 → $10
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight	$38 → $25
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86

Show Previous Ratings

Feb-12-26 04:01PM	Pacira to Report 2025 Financial Results on Thursday February 26, 2026 (GlobeNewswire)
08:00AM	Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices (GlobeNewswire)
Feb-09-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-26 10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
Jan-28-26 08:00AM	Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors (GlobeNewswire)
12:45PM	Loading…
Jan-27-26 12:45PM	Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:10PM	Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-16-26 08:30AM	Do Options Traders Know Something About Pacira BioSciences Stock We Don't? (Zacks) -7.22%
Jan-14-26 10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
Jan-13-26 08:00AM	Pacira Announces Agreement with LG Chem to Make EXPAREL Available in Select Asian-Pacific Markets (GlobeNewswire) -5.80%
Jan-12-26 10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
Jan-08-26 04:01PM	Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues (GlobeNewswire) -9.57%
Jan-07-26 08:00AM	Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences (GlobeNewswire)
Dec-31-25 10:45AM	DOMA intends to nominate three director candidates at Pacira annual meeting (TipRanks)
Dec-30-25 10:41AM	DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. (PR Newswire)
08:00AM	Loading…
Dec-18-25 08:00AM	Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care (GlobeNewswire)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-16-25 02:10PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-25 08:00AM	Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera Compared to Radiofrequency Ablation in Chronic Low Back Pain (GlobeNewswire)
Nov-26-25 04:01PM	Pacira BioSciences Files EXPAREL Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical (GlobeNewswire)
Nov-14-25 06:00PM	Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-11-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
Nov-10-25 08:09PM	DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business (PR Newswire)
Nov-07-25 12:02AM	Pacira BioSciences Inc (PCRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-25 06:30PM	Pacira (PCRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
06:10PM	Pacira (PCRX) Tops Q3 Earnings Estimates (Zacks)
05:06PM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance (GlobeNewswire)
08:00AM	Loading…
Nov-05-25 08:00AM	Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Nov-04-25 07:00AM	Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control (GlobeNewswire)
Oct-30-25 10:00AM	Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline (Zacks)
08:00AM	Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 (GlobeNewswire)
Oct-29-25 10:00AM	Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 08:00AM	Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee (GlobeNewswire)
Oct-27-25 08:00AM	Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL (GlobeNewswire)
Oct-23-25 08:00AM	Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL (GlobeNewswire)
Oct-21-25 12:10PM	Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:30AM	Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL (GlobeNewswire)
Oct-20-25 04:01PM	Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy (GlobeNewswire)
Oct-03-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-25 06:04PM	Hanesbrands, Rogers, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-06-25 03:27AM	Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... (GuruFocus.com)
Aug-05-25 08:00PM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings (Zacks)
05:35PM	Pacira (PCRX) Tops Q2 Earnings Estimates (Zacks)
04:35PM	Pacira: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:45AM	What To Expect From Pacira BioSciences Inc (PCRX) Q2 2025 Earnings (GuruFocus.com)
Jul-31-25 12:12PM	PharmaCorp Announces Filing of Annual Information Form (GlobeNewswire)
Jul-24-25 08:00AM	Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 (GlobeNewswire)
Jul-22-25 08:00AM	Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts (GlobeNewswire)
Jul-16-25 08:40AM	Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire)
Jul-10-25 11:41AM	Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement (Insider Monkey)
Jul-03-25 04:01PM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-18-25 11:06AM	Is the Options Market Predicting a Spike in Pacira BioSciences Stock? (Zacks)
08:00AM	Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient's Journey to Pain Relief and Innovation in Care at BIO 2025 (GlobeNewswire)
Jun-11-25 08:00AM	Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee (GlobeNewswire)
Jun-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 02:02PM	PharmaCorp Rx Inc. Reports First Quarter 2025 Results and Announces Non-Binding Letters of Intent to Acquire Four Pharmacies (GlobeNewswire)
May-15-25 08:00AM	Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
May-14-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
May-13-25 10:35AM	Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation (PR Newswire) -6.74%
May-09-25 11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
03:41AM	Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... (GuruFocus.com)
May-08-25 05:30PM	Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Pacira (PCRX) Q1 Earnings Surpass Estimates (Zacks)
04:11PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 05:20PM	Pacira BioSciences Q1 2025 Earnings Preview (Seeking Alpha)
10:20AM	Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
May-06-25 06:05PM	Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
May-02-25 08:00AM	Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis (GlobeNewswire)
May-01-25 05:10PM	Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates (Zacks)
10:01AM	ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:34AM	IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
08:32AM	Pharmacorp Completes Acquisition of Pre-1954 Charter Company in Ontario (GlobeNewswire)
Apr-29-25 10:01AM	Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:00AM	Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 (GlobeNewswire)
Apr-28-25 08:00AM	Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire) +5.52%
Apr-22-25 04:01PM	Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire)
Apr-21-25 12:10PM	Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again (Zacks) +5.07%
08:15AM	DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders (PR Newswire)
Apr-17-25 05:00PM	Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders (GlobeNewswire)
Apr-15-25 01:45PM	Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
Apr-11-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -8.32%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks)
10:03AM	Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act (Seeking Alpha)
09:41AM	Pacira price target raised to $28 from $25 at Truist (TipRanks)
05:53AM	Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? (Zacks)
Apr-08-25 11:29AM	PCRX Stock Soars on Exparel Patent Settlement With Generic Players (Zacks) +14.67%
Apr-07-25 04:30PM	Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks)
09:37AM	PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study (Zacks)
Apr-03-25 08:00AM	Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIKER LAUREN	Senior Vice President, Finance	Feb 02 '26	Sale	20.81	4,000	83,240	52,313	Feb 03 06:24 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Feb 02 '26	Sale	20.53	13,137	269,703	131,303	Feb 03 06:24 PM
RIKER LAUREN	Officer	Feb 02 '26	Proposed Sale	21.05	4,000	84,219		Feb 02 04:12 PM
WILLIAMS KRISTEN	Officer	Feb 02 '26	Proposed Sale	20.53	13,137	269,703		Feb 02 10:55 AM
RIKER LAUREN	Senior Vice President, Finance	Jan 05 '26	Sale	24.24	1,416	34,324	59,064	Jan 06 05:30 PM
RIKER LAUREN	Officer	Jan 05 '26	Proposed Sale	24.24	1,416	34,324		Jan 05 11:22 AM
Cross Shawn	Chief Financial Officer	Dec 09 '25	Option Exercise	16.45	15,896	261,489	72,146	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 10 '25	Option Exercise	16.45	9,104	149,761	65,354	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 09 '25	Sale	25.03	15,896	397,877	56,250	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 10 '25	Sale	25.14	9,104	228,875	56,250	Dec 11 09:47 PM
Cross Shawn	Officer	Dec 10 '25	Proposed Sale	25.14	9,104	228,912		Dec 10 04:41 PM
Cross Shawn	Officer	Dec 09 '25	Proposed Sale	25.03	15,896	397,837		Dec 09 04:31 PM
SLONIN JONATHAN	Chief Medical Officer	Nov 17 '25	Sale	24.09	3,960	95,396	178,367	Nov 19 04:32 PM
SLONIN JONATHAN	Officer	Nov 17 '25	Proposed Sale	24.09	3,960	95,396		Nov 17 10:25 AM
Cross Shawn	Chief Financial Officer	Nov 10 '25	Sale	22.09	12,060	266,405	56,250	Nov 13 04:13 PM
Cross Shawn	Officer	Nov 10 '25	Proposed Sale	22.09	12,060	266,405		Nov 10 10:02 AM
Ceesay Abraham	Director	Sep 04 '25	Sale	27.19	2,354	64,005	9,039	Sep 08 05:37 PM
Ceesay Abraham	Director	Sep 04 '25	Proposed Sale	27.19	2,354	64,005		Sep 04 09:40 AM
BIGAL MARCELO	Director	Aug 07 '25	Sale	23.67	4,912	116,267	11,393	Aug 11 04:09 PM
BIGAL MARCELO	Director	Aug 07 '25	Proposed Sale	23.67	4,912	116,279		Aug 07 03:17 PM
RIKER LAUREN	Senior Vice President, Finance	Jun 04 '25	Sale	26.21	5,578	146,208	59,564	Jun 05 05:40 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 04 '25	Sale	26.24	14,376	377,226	161,574	Jun 05 05:37 PM
RIKER LAUREN	Officer	Jun 04 '25	Proposed Sale	26.21	5,579	146,209		Jun 04 11:36 AM
WILLIAMS KRISTEN	Officer	Jun 04 '25	Proposed Sale	26.24	14,376	377,226		Jun 04 10:37 AM
GAUGLER DARYL	Officer	Mar 06 '25	Proposed Sale	23.25	500	11,625		Mar 06 12:06 PM

Open in Screener

AMRN

Amarin Corp ADR

Feb 13 • 04:00PM ET

14.74

-0.12 -0.81 %

Healthcare • Drug Manufacturers - General • Ireland • NASD

Peers: GILD REGN VRTX NBIX SRPT MDGL DVAX VKTX AKBA ITCI

| Held by: SPDW GWX

Index	-	P/E	-	EPS (ttm)	-4.17	Insider Own	0.41%	Shs Outstand	20.80M	Perf Week	-0.07%
Market Cap	306.59M	Forward P/E	103.01	EPS next Y	0.14	Insider Trans	0.00%	Shs Float	20.71M	Perf Month	-1.80%
Enterprise Value	26.43M	PEG	1.34	EPS next Q	0.03	Inst Own	20.31%	Short Float	2.02%	Perf Quarter	-9.07%
Income	-85.92M	P/S	1.35	EPS this Y	83.46%	Inst Trans	3.14%	Short Ratio	4.71	Perf Half Y	-1.99%
Sales	226.88M	P/B	0.67	EPS next Y	121.63%	ROA	-12.18%	Short Interest	0.42M	Perf YTD	5.63%
Book/sh	22.06	P/C	1.07	EPS next 5Y	76.88%	ROE	-17.35%	52W High	20.90 -29.47%	Perf Year	21.74%
Cash/sh	13.79	P/FCF	-	EPS past 3/5Y	- -24.69%	ROIC	-18.45%	52W Low	7.08 108.19%	Perf 3Y	-62.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-26.80% -11.92%	Gross Margin	37.78%	Volatility	4.83% 5.45%	Perf 5Y	-90.58%
Dividend TTM	-	EV/Sales	0.12	EPS Y/Y TTM	-115.62%	Oper. Margin	-28.07%	ATR (14)	0.79	Perf 10Y	-41.97%
Dividend Ex-Date	-	Quick Ratio	2.43	Sales Y/Y TTM	-6.31%	Profit Margin	-37.87%	RSI (14)	47.41	Recom	4.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.45	EPS Q/Q	70.03%	SMA20	-2.70%	Beta	0.85	Target Price	12.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	15.54%	SMA50	-0.17%	Rel Volume	0.49	Prev Close	14.86
Employees	275	LT Debt/Eq	0.01	Earnings	Feb 25 BMO	SMA200	-2.03%	Avg Volume	89.09K	Price	14.74
IPO	Apr 01, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	95.35% 15.25%	Trades		Volume	43,832	Change	-0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Oct-25-23	Downgrade	Jefferies	Buy → Hold	$3 → $1
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$1.30 → $3
May-06-22	Downgrade	JP Morgan	Neutral → Underweight
May-05-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10 → $3
May-05-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $3
May-04-22	Downgrade	Northland Capital	Outperform → Market Perform
May-12-21	Downgrade	Goldman	Neutral → Sell	$6 → $5
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-26-20	Initiated	Piper Sandler	Overweight	$21
May-05-20	Initiated	Northland Capital	Outperform	$15
Mar-31-20	Upgrade	Oppenheimer	Underperform → Perform
Mar-31-20	Downgrade	Jefferies	Buy → Hold	$30 → $4
Mar-31-20	Downgrade	Goldman	Buy → Neutral
Mar-13-20	Upgrade	Goldman	Neutral → Buy	$28
Mar-02-20	Initiated	Cowen	Outperform	$23
Feb-18-20	Upgrade	Citigroup	Neutral → Buy	$27 → $24
Jan-06-20	Initiated	JP Morgan	Neutral	$22
Dec-16-19	Downgrade	Stifel	Buy → Hold
Nov-20-19	Initiated	Oppenheimer	Underperform	$7

Show Previous Ratings

Feb-11-26 08:00AM	Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 (GlobeNewswire)
Jan-28-26 05:39AM	New Strong Sell Stocks for January 28th (Zacks)
Jan-22-26 10:28AM	BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? (Zacks) +7.98%
Jan-20-26 08:34AM	Do Options Traders Know Something About Amarin Stock We Don't? (Zacks)
Jan-10-26 02:57PM	Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights (Insider Monkey)
11:46AM	Loading…
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
07:00AM	Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization (GlobeNewswire)
Jan-08-26 07:00AM	Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities (GlobeNewswire) +16.89%
Dec-03-25 11:30AM	Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report? (Zacks)
Nov-09-25 04:15PM	New REDUCE-IT Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA/VAZKEPA (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients (GlobeNewswire)
Nov-03-25 08:30AM	Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 03:34PM	Amarin Corp PLC (AMRN) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 07:29AM	Amarin: Q3 Earnings Snapshot (Associated Press Finance) -11.25%
07:00AM	Amarin Reports Third Quarter 2025 Financial Results (GlobeNewswire)
09:57AM	Loading…
Oct-28-25 09:57AM	Earnings To Watch: Amarin Corp PLC (AMRN) Reports Q3 2025 Results (GuruFocus.com)
Oct-27-25 08:00AM	Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit (GlobeNewswire)
Oct-23-25 10:06AM	Do Options Traders Know Something About Amarin Stock We Don't? (Zacks)
Oct-20-25 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
Oct-15-25 08:00AM	Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT and EPA Mechanistic Data at the Canadian Cardiovascular Congress (GlobeNewswire)
Oct-06-25 09:41AM	Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Sep-26-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Sep-03-25 11:30AM	Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-31-25 08:30AM	Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 (GlobeNewswire)
Aug-30-25 08:30AM	New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups (GlobeNewswire)
Aug-25-25 08:00AM	New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 (GlobeNewswire)
Aug-22-25 09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks)
Aug-14-25 11:11AM	Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
09:55AM	Loading…
09:55AM	Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-06-25 09:40AM	Is Amarin (AMRN) Outperforming Other Medical Stocks This Year? (Zacks)
Jul-31-25 10:37AM	Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
Jul-30-25 07:05AM	Amarin: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-29-25 05:19PM	Recordati 1H Net Rev Climbs 12% to 1.3 Bln on Rare Diseases Unit Strength (Exec Edge)
12:13PM	RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9% (GlobeNewswire)
10:00AM	What To Expect From Amarin Corp PLC (AMRN) Q2 2025 Earnings (GuruFocus.com)
Jul-24-25 12:10PM	Amarin Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
10:45AM	VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales (Zacks)
Jul-23-25 07:30AM	Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025 (GlobeNewswire)
Jul-21-25 09:40AM	Are Medical Stocks Lagging DexCom (DXCM) This Year? (Zacks)
Jul-18-25 09:25AM	Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin (Zacks)
Jul-17-25 03:00PM	3 Strong Buy Breakout Stocks for Explosive Returns (Zacks)
Jul-14-25 09:06AM	Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus (Zacks)
Jul-11-25 12:12PM	FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill (Zacks)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks)
Jul-09-25 12:26PM	PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study (Zacks)
Jul-02-25 09:40AM	Are Medical Stocks Lagging Amarin (AMRN) This Year? (Zacks)
Jul-01-25 09:17AM	Moderna Stock Gains on Encouraging Flu Vaccine Data (Zacks)
Jun-27-25 10:00AM	Best Momentum Stock to Buy for June 27th (Zacks)
Jun-25-25 11:06AM	Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU (Zacks)
10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
09:28AM	Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-25 07:05AM	RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE (GlobeNewswire) +27.26%
07:00AM	Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA (Icosapent Ethyl) in Europe (GlobeNewswire)
Jun-23-25 12:34PM	SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma (Zacks)
Jun-20-25 09:46AM	Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid (Zacks) -5.93%
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-16-25 09:55AM	Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy? (Zacks)
09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-10-25 12:00PM	Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
10:00AM	Best Momentum Stocks to Buy for June 10th (Zacks)
09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks)
06:50AM	New Strong Buy Stocks for June 10th (Zacks)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +7.34%
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks)
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 11:58AM	Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines (Zacks)
May-30-25 08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 11:53AM	ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study (Zacks)
11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks)
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
09:40AM	Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? (Zacks)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-23-25 10:01AM	Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases (Zacks)
09:57AM	EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort (Zacks)
May-21-25 12:33PM	Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation (Zacks)
09:50AM	ARMP Soars 72% in a Month Following Infectious Disease Study Success (Zacks)
May-20-25 11:50AM	CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies (Zacks)
May-08-25 12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks) +5.21%
03:07AM	Amarin Corp PLC (AMRN) Q1 2025 Earnings Call Highlights: Strategic Global Expansion Amidst ... (GuruFocus.com)
May-07-25 11:01AM	Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:32AM	Amarin: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-03-25 03:02AM	Standex International Corp (SXI) Q3 2025 Earnings Call Highlights: Record Margins and Strategic ... (GuruFocus.com)
Apr-29-25 04:15PM	Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Apr-28-25 04:15PM	Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (GlobeNewswire)

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

PCRX

Pacira BioSciences Inc

AMRN

Amarin Corp ADR

Upgrade your FINVIZ experience